Completed OBSERVATIONAL NCT05085301

RapiGEN BIOCREDIT Malaria Ag RDTs WHO Prequalification Study

Clinical Performance of RapiGEN BIOCREDIT Malaria Ag RDTs for Detection of Plasmodium Infections in Patients With Symptoms Suggestive of Malaria

Sponsor: Eijkman Institute for Molecular Biology

Conditions Diagnoses Disease Malaria RDT

Interventions Rapid diagnostic test

Updated 4 times since 2021 Last updated: Oct 12, 2023 Started: Dec 1, 2021 Primary completion: May 30, 2022 Completion: May 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Diagnoses Disease and Malaria, this trial is completed. The trial is conducted by Eijkman Institute for Molecular Biology and has accumulated 4 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Nov 2023 — Jul 2024 [monthly]

Completed

Status: Not Yet Recruiting → Completed
Nov 2021 — Nov 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eijkman Institute for Molecular Biology
Foundation for Innovative New Diagnostics, Switzerland
University of Khartoum

Data source: Foundation for Innovative New Diagnostics, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia
• Khartoum, Sudan